Exelixis, Inc.
Exelixis is an oncology company that develops medicines for difficult-to-treat cancers. It offers CABOMETYX and COMETRIQ tablets and capsules for various types of cancer. The company also offers COTELLIC and MINNEBRO for specific forms of melanoma and hypertension. Exelixis is developing zanzalintinib and XB002, next-generation oral tyrosine kinase inhibitors. It has research collaborations and license agreements with several pharmaceutical companies. The company was incorporated in 1994 and is headquartered in Alameda, California.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): returns well above its cost of capital, an asset-light, cash-generative model and high, stable gross margins (pricing power).
- Creates economic value: ROIC of 37.9% against a cost of capital (WACC) of 6.3%, a spread of 31.5 percentage points.
- Pricing power: gross margin has held steady at about 96% over the last 6 years.
- Asset-light, cash-generative model: capital expenditure takes only 4.9% of revenue and free cash flow was positive in each of the last 6 years.
- Consistent growth: revenue has compounded at 18.6% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 6.8% a year over the last three years through buybacks.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data